When Medicon Valley Alliance (MVA) was founded in 1997, its focus was primarily on strengthening academic collaboration between Lund University and the University of Copenhagen. Three decades later, the organisation has evolved into a cross-border Life Science network connecting academia, healthcare, industry, and investors across one of Europe's leading Life Science regions. As MVA approaches its 30th anniversary in 2027, the ambition is clear: to strengthen Medicon Valley’s position among Europe’s leading Life Science hubs and help shape the future competitiveness of European Life Science.
Over the past 30 years, Medicon Valley Alliance has grown alongside the region it represents. What began largely as an initiative to strengthen collaboration between universities on either side of the Øresund has developed into a broader organisation bringing together companies, universities, hospitals, and other stakeholders across southern Sweden and eastern Denmark.
Today, MVA has around 300 member companies and organisations, including an increasing number of international companies looking to explore business and partnership opportunities in the region.
– The evolution of MVA mirrors the evolution of Medicon Valley itself, says Niels Abel Bonde, Chairperson of the Boardat MVA.
– We started with a strong focus on academic collaboration, but for more than two decades we have been a true triple-helix organisation, bringing academia, industry, and healthcare together to stimulate knowledge-sharing, collaboration, and innovation. This drives value to member companies and to the ecosystem broadly.
From Projects to Partnerships
MVA's activities have developed along two main tracks: developing and managing cross-border projects, and creating a meeting place for the region's Life Science community.
The organisation has a long track record of developing projects and helping partners secure public and private funding. Over the years, MVA has facilitated or co-facilitated more than €10 million in EU Interreg funding for Life Science research and innovation projects.
Recent and ongoing initiatives include DiaUnion, which focuses on screening for type 1 diabetes; The Cross-border Talent Bridge project, which aims to strengthening skills supply in Life Science and Tech across the Greater Copenhagen region; and ReproUnion, a cross-border research and innovation initiative focused on infertility.
MVA is also involved in the Cross-border Talent Bridge project, addressing talent attraction and retention, while the recently completed Nordic Life Science Academy for Startups aimed to help Life Science start-ups develop and scale.
A new EU Interreg project focused on commercialisation of Nordic SMEs within women's health has also recently been approved, with MVA taking a leading role.
The second pillar of MVA's activities is its extensive programme of events and networks. The organisation hosts 30–35 events each year, ranging from specialist MVA Network meetings in areas such as oncology, women's health, medtech and healthtech, microbiome, and R&D, to partnering events, the MVA Annual Summit, and executive-level gatherings.
Together, these activities create a marketplace where companies and other organisations can meet potential partners, exchange knowledge, and develop business opportunities.
A Different Kind of Life Science Organisation
One of MVA's defining characteristics is its cross-border nature. With Sweden and Denmark as its home markets and English as its working language, it operates across national boundaries in a way that remains relatively unusual in Europe.
Its independence is another distinguishing feature. Rather than relying on government funding, MVA operates through membership fees and project-based activities.
That model has helped shape the organisation's approach, according to MVA.
– We have to be on our toes every day, just like the privately owned companies we serve, says Niels Abel Bonde.
– Our members expect us to deliver a service, a platform, and opportunities that create real value.
The organisation's triple-helix structure is equally central. MVA brings together academic institutions, hospitals, regions, start-ups, established companies, and other organisations with different perspectives and interests.
The result is intended to be more than the sum of its parts: a network where research can find industrial applications, companies can access expertise and talent, and healthcare challenges can help shape new research and innovation.
Looking Beyond the Øresund
As MVA approaches its 30th anniversary, the organisation sees significant potential for further growth – both within Medicon Valley and beyond.
The Life Science cluster itself continues to develop, providing a natural foundation for MVA's membership and activities. But the organisation has also demonstrated that its model can attract companies from outside the region, including European companies without an established presence in Medicon Valley.
For these companies, MVA can act as a gateway to the region, helping them explore potential partnerships, customers, talent, and business opportunities.
At the same time, MVA increasingly sees its role in a wider European context.
A 2025 analysis, "Strengthening European Competitiveness – the Role of Regional Life Science Hubs", highlighted the importance of strong regional clusters in building European competitiveness. The report also provided a platform for discussion between leading Life Science hubs across Europe.
Medicon Valley's cross-border nature makes it particularly relevant to that discussion. The region connects two countries, multiple research institutions, major healthcare organisations, and a broad Life Science industry across the Øresund.
The Draghi report on European competitiveness has also explicitly highlighted Medicon Valley as an example of a region that transcends narrow national interests.
– We believe Medicon Valley has the potential to become one of Europe's leading Life Science innovation hotspots, says Sofia Wallström, CEO at Lif Sweden, the Swedish industry association representing research-based pharmaceutical companies.
– Its cross-border structure demonstrates what can be achieved when we look beyond national boundaries and build a stronger ecosystem together.
That ambition extends beyond simply making Medicon Valley more successful. MVA increasingly wants the region to contribute to the wider European conversation about innovation, competitiveness, and the future of Life Sciences.
In that sense, the organisation's next 30 years may be about taking the same idea that inspired its creation – connecting strengths across borders – and applying it on an even larger scale.
From a partnership between two universities in 1997 to a network of around 300 organisations today, MVA has spent three decades building bridges across the Øresund. Its next challenge is to help those bridges reach further into Europe.
BREAKING